FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3105862617> ?p ?o ?g. }

• W3105862617 endingPage "A732" @default.
• W3105862617 startingPage "A732" @default.
• W3105862617 abstract "Background Activation of IL-2/15Rβγc or IL-7R on immune cells using modified versions of IL-2 or IL-7 is under investigation as monotherapy, or in combination with checkpoint inhibitors, engineered T or NK cells, or neo-antigen vaccines. We previously described small synthetic peptides, unrelated to IL-2, IL-15, or IL-7, that selectively activate either IL-2/15Rβγc or IL-7R. IL-2/15Rβγc and IL-7R activation exhibit complementary effects on immune cells that when combined may offer benefits over each independent mechanism. We now report the creation of an Fc-fusion protein that incorporates both IL-2/15Rβγc and IL-7R agonist peptides, and characterize its properties in cell lines and human (PBMC) lymphocyte subpopulations. Methods Peptide agonists of IL-2/15Rβγc (MDK1169) and IL-7R (MDK1319) were separately fused to each chain of obligate heterodimeric (asymmetric) Fc molecules. The Fc-fusion was purified by protein-A and size exclusion chromatography, and characterized by LC-MS. Receptor-mediated signaling, proliferation, and cell-surface receptor expression in cell lines, PBMCs, mixed and isolated lymphocyte subpopulations were determined by flow cytometry and ELISA to evaluate effects of IL-2, IL-2v, IL-7, MDK-202 or MDK-701 (Fc-fusions of MDK1169 and MDK1319, respectively), and combinations (mixtures) of these molecules, in comparison with the dual agonist MDK-271. Results LC-MS analysis indicates MDK-271 is a heterodimeric molecule containing one copy each of MDK1169 (IL-2/15Rβγc-biased agonist) and MDK1319 (IL-7R agonist) fused to individual Fc-chains. Cell-based assay of MDK-271 demonstrates potent, fully efficacious phosphorylation of STAT5 in TF-1 cells expressing Rγc, and engineered to express either IL-2/15Rβ or IL-7Rα. PBMCs exposed ex vivo to MDK-271 exhibit additive, complementary, and synergistic effects among various lymphocyte subpopulations: CD4+Tn, Teff, Treg, Tmem; C8+Tn, Teff, Tmem; and NK cells, in this analysis. The mono-specific agonists MDK-202 and MDK-701 produce proliferative effects and signaling patterns in responsive cell lines and lymphocyte subsets similar to those induced by IL-2v (an IL-2/15Rβγc-biased mutant of IL-2) and IL-7, respectively. Combining both activities in MDK-271 induces response profiles that differ in some T-cell subsets from those of mono-specific agonists of the two receptors. Animal studies designed to understand the effects of these differences are underway. Conclusions IL-2/15Rβγc and IL-7R are both currently undergoing extensive scrutiny as potential immuno-oncology therapeutic targets. The biology of these cytokines is both overlapping and complementary in stimulating and supporting T-cell populations; and some recent evidence suggests possible superiority of the combination. Based on in vitro properties, the Fc-peptide fusion reported here, exhibiting both IL-2/15Rβγc-biased agonist and Il-7Rαγc agonist activities, could be valuable in anti-tumor therapeutic applications. Ethics Approval The use of human PBMC in this study was authorized under Minimal Risk Research Related Activities at Stanford Blood Center (SQL 79075)" @default.
• W3105862617 created "2020-11-23" @default.
• W3105862617 creator A5014389802 @default.
• W3105862617 creator A5016241973 @default.
• W3105862617 creator A5025849300 @default.
• W3105862617 creator A5033590182 @default.
• W3105862617 creator A5035774297 @default.
• W3105862617 creator A5038882344 @default.
• W3105862617 creator A5066000286 @default.
• W3105862617 creator A5068667870 @default.
• W3105862617 creator A5070762270 @default.
• W3105862617 date "2020-11-01" @default.
• W3105862617 modified "2023-09-26" @default.
• W3105862617 title "691 MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein" @default.
• W3105862617 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0691" @default.
• W3105862617 hasPublicationYear "2020" @default.
• W3105862617 type Work @default.
• W3105862617 sameAs 3105862617 @default.
• W3105862617 citedByCount "0" @default.
• W3105862617 crossrefType "journal-article" @default.
• W3105862617 hasAuthorship W3105862617A5014389802 @default.
• W3105862617 hasAuthorship W3105862617A5016241973 @default.
• W3105862617 hasAuthorship W3105862617A5025849300 @default.
• W3105862617 hasAuthorship W3105862617A5033590182 @default.
• W3105862617 hasAuthorship W3105862617A5035774297 @default.
• W3105862617 hasAuthorship W3105862617A5038882344 @default.
• W3105862617 hasAuthorship W3105862617A5066000286 @default.
• W3105862617 hasAuthorship W3105862617A5068667870 @default.
• W3105862617 hasAuthorship W3105862617A5070762270 @default.
• W3105862617 hasConcept C153911025 @default.
• W3105862617 hasConcept C170493617 @default.
• W3105862617 hasConcept C185592680 @default.
• W3105862617 hasConcept C203014093 @default.
• W3105862617 hasConcept C2776090121 @default.
• W3105862617 hasConcept C2778690821 @default.
• W3105862617 hasConcept C2778938600 @default.
• W3105862617 hasConcept C553184892 @default.
• W3105862617 hasConcept C55493867 @default.
• W3105862617 hasConcept C74172505 @default.
• W3105862617 hasConcept C86803240 @default.
• W3105862617 hasConcept C8891405 @default.
• W3105862617 hasConcept C95444343 @default.
• W3105862617 hasConcept C98119934 @default.
• W3105862617 hasConceptScore W3105862617C153911025 @default.
• W3105862617 hasConceptScore W3105862617C170493617 @default.
• W3105862617 hasConceptScore W3105862617C185592680 @default.
• W3105862617 hasConceptScore W3105862617C203014093 @default.
• W3105862617 hasConceptScore W3105862617C2776090121 @default.
• W3105862617 hasConceptScore W3105862617C2778690821 @default.
• W3105862617 hasConceptScore W3105862617C2778938600 @default.
• W3105862617 hasConceptScore W3105862617C553184892 @default.
• W3105862617 hasConceptScore W3105862617C55493867 @default.
• W3105862617 hasConceptScore W3105862617C74172505 @default.
• W3105862617 hasConceptScore W3105862617C86803240 @default.
• W3105862617 hasConceptScore W3105862617C8891405 @default.
• W3105862617 hasConceptScore W3105862617C95444343 @default.
• W3105862617 hasConceptScore W3105862617C98119934 @default.
• W3105862617 hasIssue "Suppl 3" @default.
• W3105862617 hasLocation W31058626171 @default.
• W3105862617 hasOpenAccess W3105862617 @default.
• W3105862617 hasPrimaryLocation W31058626171 @default.
• W3105862617 hasRelatedWork W1570245632 @default.
• W3105862617 hasRelatedWork W1656439669 @default.
• W3105862617 hasRelatedWork W1978943609 @default.
• W3105862617 hasRelatedWork W1979277488 @default.
• W3105862617 hasRelatedWork W2012137498 @default.
• W3105862617 hasRelatedWork W2105646872 @default.
• W3105862617 hasRelatedWork W2146890397 @default.
• W3105862617 hasRelatedWork W2380122544 @default.
• W3105862617 hasRelatedWork W2551016668 @default.
• W3105862617 hasRelatedWork W3160389761 @default.
• W3105862617 hasVolume "8" @default.
• W3105862617 isParatext "false" @default.
• W3105862617 isRetracted "false" @default.
• W3105862617 magId "3105862617" @default.
• W3105862617 workType "article" @default.